Control first, tolerance second: biologics as enablers of allergen immunotherapy in severe allergic asthma. (PubMed, Front Allergy) - Sep 25, 2026 - "This narrative review synthesizes the immunological rationale and clinical evidence supporting sequential biologic-AIT combination, with emphasis on omalizumab as the best-studied adjunct and emerging data on dupilumab and tezepelumab. The novelty of this framework lies in reframing biologics not merely as symptom-control agents but as facilitators that unlock a previously inaccessible disease-modifying intervention, potentially shifting severe allergic asthma management from control toward durable immunological remission. We conclude that biologic-enabled AIT is a promising but insufficiently defined strategy, and outline the prospective trials, standardized phenotyping, and safety registries needed to establish it as an evidence-based clinical pathway."
IO biomarker • Journal • Review • Allergic Rhinitis • Allergy • Asthma • Immunology • Infectious Disease • Inflammation • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL5 • TSLP
|
|
A Hoheisel; B C Frye; B Jentzsch; D Stolz; I Cherrez-Ojeda; J A Alvarado Castillo; K Gashynova; S Fähndrich; S Müller
|